CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease.
Except for a handful of inherited cases related to known gene defects, Parkinson's disease (PD) is a sporadic neurodegenerative disease of unknown etiology. There is increasing evidence that inflammation and proliferation of microglia may contribute to the neuronal damage seen in the nigro-striatal dopaminergic system of PD patients. Microglia events that participate in neuronal injury include the release of pro-inflammatory and neurotoxic factors. Characterizing these factors may help to prevent the exacerbation of PD symptoms or to remediate the disease progression. In rodents, the nigro-striatal system exhibits high expression of the chemokine receptor CXCR4. Its natural ligand CXCL12 can promote neuronal apoptosis. Therefore, the present study investigated the expression of CXCR4 and CXCL12 in post-mortem brains of PD and control (non-PD) individuals and in an animal model of PD. In the human substantia nigra (SN), CXCR4 immunoreactivity was high in dopaminergic neurons. Interestingly, the SN of PD subjects exhibited higher expression of CXCR4 expression and CXCL12 than control subjects despite the loss of dopamine (DA) neurons. This effect was accompanied by an increase in activated microglia. However, results from post-mortem brains may not provide indication as to whether CXCL12/CXCR4 can cause the degeneration of DA neurons. To examine the role of these chemokines, we determined the levels of CXCL12 and CXCR4 in the SN of MPTP-treated mice. MPTP produced a time-dependent up-regulation of CXCR4 that preceded the loss of DA neurons. These results suggest that CXCL12/CXCR4 may participate in the etiology of PD and indicate a new possible target molecule for PD.
Shimoji
Mika
M
Department of Neuroscience, Georgetown University Medical Center, Research Building, Room EP04, 3970 Reservoir Rd, NW, Box 571464, Washington, DC 20057, USA.
Pagan
Fernando
F
Healton
Edward B
EB
Mocchetti
Italo
I
D000704:Analysis of Variance; D000818:Animals; D002135:Calcium-Binding Proteins; D054377:Chemokine CXCL12 / Q000235:genetics / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D020267:MPTP Poisoning / Q000139:chemically induced / Q000473:pathology; D051379:Mice; D008840:Microfilament Proteins; D017628:Microglia / Q000473:pathology; D010300:Parkinson Disease / Q000209:etiology / Q000473:pathology*; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D011180:Postmortem Changes; D019718:Receptors, CXCR4 / Q000235:genetics / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism*; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
C112986:AIF1 protein, human; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D002135:Calcium-Binding Proteins; D054377:Chemokine CXCL12; D004268:DNA-Binding Proteins; D008840:Microfilament Proteins; D019718:Receptors, CXCR4; D014446:Tyrosine 3-Monooxygenase; D010751:Phosphopyruvate Hydratase